相关实验视频

Updated: May 4, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

用远端转移性分化甲状腺癌的分子变化来对放射性的折射性进行风险分层

Zhuanzhuan Mu^1,2, Xin Zhang^1,2, Dongquan Liang³

¹Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, Beijing 100730, China.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

|March 8, 2024

概括

放射性耐火差异化甲状腺癌 (RAIR-DTC) 与特定的基因突变有关,包括BRAF和TERT促进体. 分子风险分层 (MRS) 可以预测 RAIR-DTC 患者的结果和指导治疗.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
分子生物学分子生物学

背景情况:

放射性耐火分化甲状腺癌 (RAIR-DTC) 的治疗选择有限.
在DTC中RAI折射率的遗传基础尚未完全理解.
早期识别和向治疗对于改善患者的治疗结果至关重要.

研究的目的:

调查转移性DTC中遗传变化和RAI折射性之间的相关性.
开发和验证RAIR-DTC的分子风险分层 (MRS) 模型.

主要方法:

对26个基因小组 (ThyroLead) 的下一代测序在220名转移DTC的成年患者中进行.
患者被分为RAIR-DTC和非RAIR组.
分子风险分层 (MRS) 是基于已识别的遗传变化和RAI的折射性而开发的.

主要成果:

在90%的患者中发现了基因变异,RAIR-DTC组中BRAF,TERT促进器和TP53突变显著更为普遍.
在非RAIR集团中,RET合并更为常见.
BRAF和TERT促进子突变独立预测RAIR-DTC,占67.6%的病例. MRS与RAI的折射率有很强的关联 (P<0.001).

结论:

特定的分子变化,特别是BRAF和TERT促进子突变,与DTC中的RAI折射性密切相关.
开发的MRS模型是预测临床结果的宝贵工具.
对于RAIR-DTC,MRS可以帮助指导基于精度的治疗干预.

关键词:

有差异化的甲状腺癌.RAI 的折射性是什么遥远的转移遥远的转移遗传变化遗传变化分子风险分层化分子风险分层化.

更多相关视频

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...